Skip to main content
. 2020 Jul 1;40(8):355–369. doi: 10.1002/cac2.12069

TABLE 2.

Univariate and multivariate analyses of prognostic factors associated with overall survival of HCC patients

Univariate analysis Multivariate analysis
Variable P value HR (95% CI) P value HR (95% CI)
Gender (female vs. male) 0.543 1.241 (0.619‐2.491)
Age (> 50 vs. ≤50 years) 0.303 1.270 (0.806‐2.000)
AFP level (> 400 vs. ≤400 ng/mL) 0.197 1.347 (0.857‐2.119)
HBV infection (yes vs. no) 0.826 0.928 (0.477‐1.805)
Tumor number (multiple vs. single) <0.001 4.319 (2.734‐6.822) <0.001 4.174 (2.586‐6.738)
Tumor size (> 5 vs. ≤5 cm) <0.001 3.157 (1.817‐5.485) 0.016 2.028 (1.138‐3.614)
Serum ALT (> 40 vs. ≤40 U/L) 0.244 1.308 (0.833‐2.054)
Serum AST (> 40 vs. ≤40 U/L) 0.049 1.575 (1.003‐2.474) 0.135 1.439 (0.893‐2.317)
Albumin (> 35 vs. ≤35 g/L) <0.001 0.886 (0.833‐0.943) 0.001 0.897 (0.842‐0.955)
Total bilirubin (> 21 vs. ≤21 μmol/L) 0.092 1.673 (0.920‐3.041)
Prothrombin time (> 13.5 vs. ≤13.5 s) 0.502 1.199 (0.705‐2.039)
Macrovascular invasion (yes vs. no) 0.005 2.863 (1.368‐5.995) 0.120 1.827 (0.855‐3.902)
Differentiation grade (III+IV vs. I+II) 0.166 1.375 (0.876‐2.157)
Cirrhosis (yes vs. no) 0.347 1.244 (0.790‐1.959)
TESC level (high vs. low) 0.018 1.729 (1.100‐2.719) 0.011 1.863 (1.155‐3.005)

HCC: hepatocellular carcinoma; HR: hazard ratio; CI: confidence interval; HBV: hepatitis B virus; AFP: alpha‐fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TESC: Tescalcin.